Argos Therapeutics

Argos Therapeutics, Inc. is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells - the master switch that turns the immune system on or off.

Company Growth (employees)
Type
Public
HQ
Durham, US
Founded
1997
Size (employees)
136 (est)
Argos Therapeutics was founded in 1997 and is headquartered in Durham, US

Argos Therapeutics Office Locations

Argos Therapeutics has an office in Durham
Durham, US (HQ)
4233 Technology Dr

Argos Therapeutics Metrics

Argos Therapeutics Financial Metrics

Revenue (2015)

$518.3 k

Revenue growth (2014-15), %

(74%)

Net income (2015)

($74.8 m)

Market capitalization (21-Mar-2017)

$37.3 m

Closing share price (21-Mar-2017)

$0.9
Argos Therapeutics's current market capitalization is $37.3 m.
Argos Therapeutics's revenue was reported to be $518.3 k in FY, 2015 which is a 73.7% decrease from the previous period.
FY, 2014FY, 2015

Revenue

$2 m$518.3 k

Revenue growth, %

(74%)

Operating expense total

$54.1 m$73.1 m

EBIT

($52.1 m)($72.5 m)

EBIT margin, %

(2641%)(13996%)

Net Income

($53.3 m)($74.8 m)
FY, 2014FY, 2015

Cash From Operating Activities

$3.9 m($31.1 m)

Argos Therapeutics Market Value History

Argos Therapeutics Online Presence

Argos Therapeutics Company Life

You may also be interested in